Aim(s): The present study aimed to discover whether there is an association between thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels and recurrent miscarriage (RM). In particular, TAFI antigen levels of women with RM were compared with those of a control group of women with previous uncomplicated pregnancies.

Method(s): Group 1 comprised 48 women with RM, defined as the occurrence of two or more fetal losses before 20 weeks of gestation. Group 2 (the control group) was made up of 40 women who had undergone at least two healthy pregnancies and had no history of miscarriage. Group 1 was then stratified in to two groups according to the number of pregnancy losses and group 1A (2 pregnancy losses) consisted of 22 women whereas group 1B (three or more pregnancy losses) consisted of 26 women.

Results: No difference was observed with regard to serum TAFI antigen levels between groups 1 and 2. There was also no statistical difference in serum TAFI antigen levels between group 1A and group 1B.

Conclusion: The findings of the current study indicated that TAFI antigen levels are not associated with RM. Further multi-centric research with more subjects is needed to better evaluate the role of TAFI in RM.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tafi antigen
20
antigen levels
20
pregnancy losses
12
group
9
fibrinolysis inhibitor
8
inhibitor tafi
8
recurrent miscarriage
8
control group
8
group women
8
losses consisted
8

Similar Publications

Article Synopsis
  • Hormone therapy (HT) is shown to decrease protein carbonylation (PC) and improve clot lysis in postmenopausal women, who generally have issues with fibrinolysis.
  • In a study with 150 women, those with higher baseline PC (above 2.07 nM/mg) experienced longer clot lysis times and increased prothrombotic markers, while HT reduced PC and improved clot lysis rates.
  • The findings suggest that HT effectively lowers PC levels and enhances fibrinolysis in postmenopausal women with elevated PC, regardless of the type of HT used.
View Article and Find Full Text PDF

Background: Thrombin is a critical protease modulating thrombosis as well as inflammation, which are one of the main pathophysiological mechanisms in sickle vasculopathy, and its levels were reported to be high in sickle cell disease (SCD). The thrombin-thrombomodulin complex activates the TAFI inhibitor of fibrinolysis, which acts by reducing plasmin affinity for its substrate thus hindering fibrinolysis.

Objective: We aimed to determine the influence of the Thr325Ile single nucleotide polymorphism (SNP) on TAFI antigen levels and potential effects on the severity of SCD in a cohort of Egyptian patients.

View Article and Find Full Text PDF

Introduction: Post-thrombotic syndrome (PTS) is a frequent chronic complication of deep venous thrombosis (DVT). Biomarkers are potentially valuable clinical tools for handling PTS. The purpose of this review was to examine which biomarkers are associated with the development of PTS in adults with lower extremity DVT.

View Article and Find Full Text PDF

Background And Aims: Type 2 diabetes mellitus (T2DM) individuals are at a higher risk of developing diabetes complications, with approximately 80% complication-related mortality. The increased morbidity and mortality among T2DM patients are partly due to dysregulated hemostasis. This study determined the quality of glycemic control in T2DM and its association with markers of coagulation and inhibitors of fibrinolysis.

View Article and Find Full Text PDF

Recurrent miscarriage (RM) is a major reproductive health issue. RM is a multi-factorial disease, and is affected by environmental, genetic, and epigenetic factors. Genetics has a common role in recurrent miscarriage occurrence.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!